KidneyX Innovation Accelerator

What KidneyX Innovation Accelerator does

KidneyX Innovation Accelerator (KidneyX) is a public-private partnership between the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN), launched in 2017 and headquartered in Washington, D.C. ASN serves as the secretariat and operational host. KidneyX's core function is accelerating innovation in the prevention, diagnosis, and treatment of kidney diseases — a market affecting approximately 850 million people globally and roughly 37 million Americans, with U.S. dialysis and kidney care representing a $114 billion market. The program operates through a portfolio of prize competitions (currently 8 active and historical phases including Redesign Dialysis Phase 1 and 2, Patient Innovator Challenge, COVID-19 Kidney Care Challenge, Artificial Kidney Prize Phase 1 and 2, Sustainability Prize, and EMPOWER Prize Challenge) with total prize pools ranging from $70K to $9.2M per competition and cumulative disbursement exceeding $28M.

KidneyX does not develop proprietary technology itself; instead, it curates problem statements, selects winners via competitive application processes, disburses milestone-based prize funding, and provides winners with regulatory guidance, clinical trial design support, and connections to investor networks and FDA pathways. Supporting infrastructure includes the Resource Center, the KRT Technology Roadmap (developed with the Kidney Health Initiative), and the Solver Community platform. The program's mandate addresses a market failure where neither public nor private sector investment has been adequate to the scale of need: living kidney donation has stagnated at fewer than 7,000 annually for two decades, nearly 100,000 Americans are on transplant waitlists with 13+ dying daily, and dialysis has seen limited disruptive innovation.

The business model is grant- and prize-based, funded primarily through U.S. federal appropriations ($5M in FY20 and $5M in President Biden's first budget) with additional co-funding from private partners such as the National Kidney Foundation. KidneyX is governed by a Steering Committee chaired by Dr. John R. Sedor (Cleveland Clinic) and includes representatives from HHS, NIH, FDA, MIT, Baylor College of Medicine, ASN, NKF, and patient advocates. The organization operates with 11-50 staff and is not a venture-backed or publicly traded entity; it is a collaborative government-association initiative rather than a commercial enterprise.

Name

KidneyX Innovation Accelerator

Legal name

Kidney Innovation Accelerator (KidneyX)

Website

https://kidneyx.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

KidneyX is a public-private partnership between HHS and ASN that accelerates kidney disease innovation through prize competitions, having disbursed over $28M across 8 competition phases to support 100+ innovators developing dialysis, artificial kidney, and donor-focused solutions.

Ownership category

akta.pro rank

Product category

Healthcare Innovation Funding

NAICS

Voluntary Health Organizations (813212), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

akta.pro secondary industry

Renal Transplant Medicine (Pre/Post-Transplant Care) (HLAKAHAD)

Keywords

• Kidney innovation accelerator
• Prize competitions
• Kidney disease treatment
• Healthcare innovation funding
• Public-private partnership

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Federal Appropriations: KidneyX is funded through U.S. federal appropriations from HHS, including $5M for FY20 and $5M included in President Biden's first federal budget proposal. The program disburses prize funding to competition winners.
2. Public-Private Partnership Funding: As a partnership between HHS and ASN, KidneyX leverages combined resources from government and the private sector to fund prize competitions and support kidney innovation ecosystem.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

KidneyX Innovation Accelerator is a public-private partnership between the U.S. Department of Health and Human Services and the American Society of Nephrology that accelerates innovation in kidney disease prevention, diagnosis, and treatment through prize competitions. It disburses non-dilutive prize funding (totaling over $28M across multiple phases) to researchers, startups, and innovators developing dialysis technologies, artificial kidneys, xenotransplantation, regenerative medicine, and patient-centered solutions. It also provides regulatory guidance, clinical trial resources, and a community platform for the kidney innovation ecosystem.

Product overview

KidneyX Innovation Accelerator is a public-private partnership between the US Department of Health and Human Services and the American Society of Nephrology that accelerates innovation in kidney disease treatment through prize competitions. The organization operates a portfolio of eight distinct prize competitions (Redesign Dialysis Phase 1 and 2, Patient Innovator Challenge, COVID-19 Kidney Care Challenge, Artificial Kidney Prize Phase 1 and 2, EMPOWER Prize Challenge, and Sustainability Prize) ranging from $70K to $9.2M in total prize value. Supporting infrastructure includes the Resource Center providing regulatory guidance and educational materials, the KRT Technology Roadmap for research prioritization, and the Solver Community for innovator networking. The portfolio collectively supports innovations across dialysis technology, artificial kidneys, xenotransplantation, regenerative medicine, patient-focused solutions, and sustainable healthcare delivery.

Differentiator

Problem solved

Functional benefit

Products and services

• EMPOWER Prize Challenge A $4 million national prize competition to accelerate innovations supporting living kidney donors, addressing barriers including public awareness, donor interventions, donor readiness (BMI management, smoking cessation), donor-centered outcomes tracking, and center practices to reduce administrative delays. Launched April 2026.
• KidneyX Sustainability Prize A prize competition awarding up to $7.25 million for innovations to reduce water or power used during dialysis, with Track A for solutions already in practice and Track B for scalable prototypes. Launched 2023.
• Artificial Kidney Prize Phase 2 A two-track competition with $10.5 million available for up to nine winners accelerating development of an artificial kidney. Track One supports bioartificial kidney prototypes ($4.5M); Track Two develops enabling tools ($6M). Launched August 2022.
• Artificial Kidney Prize Phase 1 A $3.9 million competition to accelerate development of artificial kidneys toward human clinical trials by supporting component or integrated prototype solutions. Launched 2021 with 6 winners.
• COVID-19 Kidney Care Challenge A $300K prize competition seeking demonstrated solutions to reduce transmission of COVID-19 among people with kidney disease and reduce risk of kidney damage. Launched 2020 with 15 winners.
• Patient Innovator Challenge A $70K prize competition, funded by the National Kidney Foundation, challenging individuals and organizations for ideas on improving therapeutic options and quality of life for people with kidney diseases. Launched 2020 with 25 winners.
• Redesign Dialysis Phase 2 A $3 million competition challenging participants to build and test prototype solutions that can replicate normal kidney functions or improve dialysis access. Launched 2020 with 6 winners.
• Redesign Dialysis Phase 1 KidneyX's inaugural $1.125 million prize competition asking innovators to accelerate development and commercialization of next-generation dialysis products. Launched 2019 with 15 winners.

Quantifiable outcome

• Over 100 innovators supported through prize competitions across 8 major competition phases
• +2 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core, major and supporting.

• U.S. Department of Health and Human Services (HHS)coreStrategic or Co-development Partner · 1 January 2018HHS is the federal government partner in KidneyX, providing appropriations funding and federal government legitimacy. ASN and HHS formalized KidneyX via Memorandum of Understanding in 2018. HHS provides the regulatory and policy framework, while KidneyX operates under HHS auspices.
• American Society of Nephrology (ASN)coreStrategic or Co-development Partner · 1 January 2016ASN serves as the secretariat and private-sector partner for KidneyX. ASN testified to Congress in 2014 about prizes for kidney replacement therapy, committed to serving as secretariat at the 2016 White House Organ Summit, and formalized the partnership with HHS in 2018. ASN provides the medical community network and operational infrastructure.
• National Kidney FoundationmajorGTM or Marketing PartnerNKF co-sponsored the Patient Innovator Challenge, providing $70K in prize funding. NKF represents the kidney patient community and provides patient advocacy resources through the KidneyX Resource Center.
• Office of the National Coordinator for Health Information Technology (ONC)supportingStrategic or Co-development PartnerONC collaborates with HHS and ASN on data standardization and health information technology improvements across the kidney care ecosystem, announced alongside the EMPOWER Prize Challenge in 2026.
• Kidney Health Initiative (KHI)coreStrategic or Co-development PartnerKHI is an ASN public-private partnership that develops the KRT Technology Roadmap guiding KidneyX priorities. KHI provides regulatory resources, clinical trial design guidance, and patient engagement frameworks.
• Food and Drug Administration (FDA)supportingStrategic or Co-development PartnerFDA collaborates through the Breakthrough Devices Program and provides regulatory guidance resources for KidneyX competition participants. FDA has granted Breakthrough Device Designation to KidneyX winners.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Cancer Moonshot: Federal cancer-focused initiative with similar public-private partnership and cross-agency convening model to KidneyX, applied to oncology rather than nephrology.
• NIH NCATS: National Center for Advancing Translational Sciences operates federal translational science programs that de-risk early-stage therapeutic development. Broader in scope than KidneyX but operates a similar federal bridge between research and commercialization.

Others

• Outset Medical: KidneyX competition winner (COVID-19 Kidney Care Challenge) that commercialized the Tablo Hemodialysis System. Included as a KidneyX-validated portfolio company rather than a direct peer.
• United Therapeutics: Acquired KidneyX winner IVIVA Medical, demonstrating that KidneyX pipeline feeds into major strategic acquirers in organ manufacturing and xenotransplantation. Comparable in disease space but not in business model.

Direct peers

• BARDA DRIVe: BARDA's Division of Research, Innovation, and Ventures is a fellow HHS-operated innovation accelerator using prize competitions and venture-style funding to de-risk breakthrough health technologies — directly comparable mission and federal structure to KidneyX.
• XPRIZE Foundation: XPRIZE operates large-scale incentive prize competitions across health and other domains, including past health-focused prizes. Highly comparable prize-competition GTM and innovator pipeline-building model to KidneyX.
• FasterCures (Milken Institute): A non-profit center that accelerates medical R&D by connecting stakeholders across patients, researchers, regulators, and investors. Comparable mission of removing barriers to biomedical innovation and similar cross-sector convening model to KidneyX.
• Cures Within Reach: Non-profit that funds proof-of-concept clinical trials for repurposed therapies; similar prize-style funding of underfunded disease areas with a comparable accelerator/grant-maker identity.

Emerging players

• National Kidney Foundation: Major kidney-focused non-profit that co-sponsors KidneyX challenges and overlaps in patient advocacy and kidney community convening. Adjacent rather than directly competitive; partnership role confirmed by NKF sponsorship of Patient Innovator Challenge.
• American Kidney Fund: Voluntary health organization supporting kidney patients through financial assistance and education; comparable non-profit status and kidney focus but serves patients directly rather than funding R&D.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Kidney_X
• LinkedInlinkedin.com/company/kidneyx

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KidneyX Innovation Accelerator